Verve Therapeutics, Inc.

VERV

US92539P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.16 ^USD	-0.96%		-7.23%	-55.81%

Apr. 03	Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	MT
Apr. 02	Sector Update: Health Care Stocks Slide Late Afternoon	MT

Verve Therapeutics, Inc. announced that it has received $22.96317 million in funding from Eli Lilly and Company

December 30, 2023

Verve Therapeutics, Inc closed the private placement of 2,296,317 shares at an issue price of price of $10 per share on December 1, 2023.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ELI LILLY AND COMPANY	733.5 USD	+1.19%	+0.99%	661B
	VERVE THERAPEUTICS, INC.	6.16 USD	-0.96%	-7.23%	517M

Latest news about Verve Therapeutics, Inc.

Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating	Apr. 03	MT
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 02	MT
Top Midday Decliners	Apr. 02	MT
Looming Factory Orders, Job Openings Data Prompt Lower Premarket Action for US Equity Futures	Apr. 02	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	Apr. 02	MT
Sector Update: Health Care	Apr. 02	MT
Verve Therapeutics Pauses Heart-1 Trial After Serious Adverse Events; Shares Fall Pre-Bell	Apr. 02	MT
Top Premarket Decliners	Apr. 02	MT
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels	Apr. 02	RE
Verve Therapeutics, Inc. Announces Updates on its PCSK9 Program	Apr. 02	CI
Verve Therapeutics Q4 Net Loss Widens, Collaboration Revenue Rises; Beats Estimates; Shares Rise	Feb. 27	MT
Verve Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Verve Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Certain Restricted Stock Units of Verve Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
Certain Options of Verve Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
Certain Common Stock of Verve Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JAN-2024.	Jan. 27	CI
Transcript : Verve Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04:30 PM	Jan. 08
Google Ventures adds partner to back AI, open source startups	Dec. 13	RE
Verve Therapeutics Closes Public Offering of Common Shares	Dec. 01	MT
Verve Therapeutics, Inc. announced that it has received $22.96317 million in funding from Eli Lilly and Company	Nov. 30	CI
Sector Update: Health Care Stocks Advance Premarket Wednesday	Nov. 29	MT
Rate Outlooks Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday	Nov. 29	MT
Verve Therapeutics Shares Tumble Premarket After Stock Sales	Nov. 29	DJ
Verve Therapeutics Prices $148 Million Common Stock Offering, Concurrent Private Placement; Shares Slump Pre-Bell	Nov. 29	MT
Verve Therapeutics Prices Offering of Common Shares, Concurrent Private Placement for Proceeds of $148 Million	Nov. 29	MT

Chart Verve Therapeutics, Inc.

Duration

Period

More charts

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Companyâs lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Verve Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.16 USD

Average target price

31.22 USD

Spread / Average Target

+406.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VERVE THERAPEUTICS, INC.	-55.81%	517M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research